SCHEMBL21296913

SCHEMBL21296913

O=C(O)c1nn[nH]c1Oc1ccc(-c2cc(Cl)cc(Cl)c2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 2/20 0.45
RXRB P28702 2/20 0.45
HAO1 Q9UJM8 4/20 0.41
MCL1 Q07820 2/20 0.40
BCL2L1 Q07817 1/20 0.40
CDH1 P12830 1/20 0.39
CTNNB1 P35222 1/20 0.39
TCF7L2 Q9NQB0 1/20 0.39
PRKAG1 P54619 3/20 0.37
PRKAA1 Q13131 3/20 0.37
PRKAB1 Q9Y478 3/20 0.37
ALPL P05186 2/20 0.37
CA12 O43570 1/20 0.37
PTPN1 P18031 1/20 0.36
DUSP3 P51452 1/20 0.36
CHEK2 O96017 2/20 0.36
PRKAB2 O43741 2/20 0.36
PRKAA2 P54646 2/20 0.36
PRKAG3 Q9UGI9 2/20 0.36
PRKAG2 Q9UGJ0 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21296963 0.91 HAO1 (0.49) HAO1CDH1CTNNB1TCF7L2ALPL
SCHEMBL21312624 0.89 HAO1 (0.47) HAO1PRKAG1PRKAA1PRKAB1PTPN1
SCHEMBL21296934 0.86 RXRA (0.46) RXRARXRBHAO1MCL1BCL2L1
SCHEMBL29799196 0.86 RXRA (0.46) RXRARXRBHAO1MCL1BCL2L1
SCHEMBL21296890 0.86 HAO1 (0.52) HAO1CDH1CTNNB1TCF7L2ALPL
SCHEMBL21296872 0.86 HAO1 (0.44) HAO1MCL1BCL2L1PRKAG1PRKAA1
SCHEMBL24154378 0.85 KMO (0.41) HAO1CDH1CTNNB1TCF7L2PRKAG1
SCHEMBL21296854 0.85 HAO1 (0.44) HAO1MCL1PRKAG1PRKAA1PRKAB1
SCHEMBL21312672 0.84 HAO1 (0.41) HAO1MCL1PRKAG1PRKAA1PRKAB1
SCHEMBL25465250 0.83 PRKAG1 (0.39) HAO1MCL1PRKAG1PRKAA1PRKAB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11389456-B2 Compounds and methods for treating oxalate-related diseases OXALURX, INC. (US) 2022-07-19 US disclosed
US-20200390778-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. 2020-12-17 US disclosed
US-20200390778-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. 2020-12-17 US disclosed
WO-2019165159-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. (US) 2019-08-29 WO disclosed
WO-2019165159-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. (US) 2019-08-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200390778-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES XDH, PNPO, LOX RXRA 1818/4885RXRB 1742/4885HAO1 14/4885
US-11389456-B2 Compounds and methods for treating oxalate-related diseases XDH, PNPO, LOX RXRA 1818/4885RXRB 1742/4885HAO1 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.